Cinchocaine

As a classic variety of long-acting amide local anesthetics, cinchocaine reversibly blocks the sodium ion channels on the nerve cell membrane to inhibit the generation and conduction of nerve impulses. Its anesthetic potency is 12–15 times that of procaine, with a duration of action of approximately 2–6 hours. Clinically, it is mainly used for epidural block, subarachnoid anesthesia and surface anesthesia. It can also be combined with glucocorticoids to prepare external preparations to relieve pain caused by hemorrhoids, perianal diseases and local soft tissue injuries, and is suitable for adult patients requiring long-term anesthesia or postoperative analgesia. Due to its high toxicity, low-concentration local administration is mostly adopted in clinical practice, and the risk of medication in children needs to be strictly evaluated.

The global local anesthetic market size was approximately USD 4.8 billion in 2023, with a compound annual growth rate of around 4.2%, among which long-acting amide anesthetics account for 37% of the overall market share. As cinchocaine's clinical positioning is biased towards special-scenario anesthesia and external compound preparations, its overall market size is relatively small. At present, the global production capacity is mainly concentrated in Europe, India and southwestern China. The original research product has been off-patent for many years, and there are fewer than 10 generic drug manufacturers worldwide. Domestic clinical application has long relied on imported API. In recent years, with the increasing demand for external analgesic preparations, the annual demand growth rate of domestic cinchocaine API has stabilized at around 6%.

The original research enterprise of cinchocaine is Bayer AG of Germany, with the original brand name Nupercaine, and the core compound patent expired globally around 1970. The main dosage forms approved for the original product include injection (10ml:10mg) and external ointment (1% specification). Both the original injection and external ointment have been included in the FDA Reference Listed Drug Catalog, but have not been included in the China Listed Drug Catalog Set yet. Up to now, there is no A-status registration number for cinchocaine on the API Registration Platform of China CDE. Only imported external compound preparations have been approved in China, and no single-agent preparation or domestic preparation has been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of cinchocaine impurity reference standards, which fully meet the reference substance requirements in the stages of API R&D, quality research and declaration. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations. Complete structure confirmation and quality research data can be provided with the goods, which effectively shortens the R&D and declaration cycle of customers.